5 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the five most promising gene editing stocks according to hedge funds. If you want to find out why December 2023 was the month for the gene editing industry, then check out 12 Most Promising Gene Editing Stocks According to Hedge Funds.

5. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Investors In Q3 2023: 45

Exact Sciences Corporation (NASDAQ:EXAS) is an American company that sells DNA testing products and kits. It is one of the top rated stocks on our list as analysts have rated the shares as Strong Buy on average and set an average share price target of $92.82.

During Q3 2023, 45 out of the 910 hedge funds part of Insider Monkey’s database held a stake in Exact Sciences Corporation (NASDAQ:EXAS). Catherine D. Wood’s ARK Investment Management was the firm’s largest shareholder as it held 6.2 million shares that were worth $428 million.

4. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Investors In Q3 2023: 50

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company developing treatments for a wide variety of diseases such as those involving the eyes and the skin. The firm also focuses on treating colorectal cancer. The coming months might be crucial for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as the firm is seeking U.S. approval for a treatment for chronic obstructive pulmonary disorder (COPD).

As of September 2023 end, 50 out of the 910 hedge funds covered by Insider Monkey’s research were the firm’s shareholders. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s biggest investor among these is D. E. Shaw’s D E Shaw due to its $304 million stake.

3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Investors In Q3 2023: 57

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s treatments seek to target fibrosis, severe pain, high blood pressure, and other ailments. December 2023 was a blockbuster month for the firm as its Sickle Cell Disease treatment secured approval from the FDA to become the first of its kind using gene editing.

By the end of this year’s third quarter, 57 out of the 910 hedge funds surveyed by Insider Monkey had held a stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Jim Simons’ Renaissance Technologies was the largest shareholder as it owns 1.6 million shares that are worth $578 million.

2. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Investors In Q3 2023: 73

Pfizer Inc. (NYSE:PFE) is one of the biggest healthcare and pharmaceutical companies in the world. 2023 has been a rather torrid month for the stock, as the shares are down 47% year to date amidst a flurry of pessimism which included disappointing guidance for 2024.

Insider Monkey scoured through 910 hedge funds for their third quarter of 2023 shareholdings and found that 73 had invested in the company. Pfizer Inc. (NYSE:PFE)’s biggest hedge fund investor is D. E. Shaw’s D E Shaw courtesy of its $436 million stake.

1. NVIDIA Corporation (NASDAQ:NVDA)

Number of Hedge Fund Investors In Q3 2023: 180

NVIDIA Corporation (NASDAQ:NVDA) is a semiconductor company that designs and sells graphics processing units (GPUs). It is also a key player in the gene editing industry through its Clara computing platform that leverages A.I. to accelerate genomics.

As Q3 2023 ended, 180 out of the 910 hedge funds part of Insider Monkey’s database had bought and owned NVIDIA Corporation (NASDAQ:NVDA)’s shares. Rajiv Jain’s GQG Partners was the largest shareholder through its $6.1 billion investment.

Disclosure: None. You can also take a look at 12 Most Profitable Cheap Stocks To Buy and Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks.

Follow Insider Monkey on Twitter